EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
Recent Searches
The evolving policy landscape and implications for commercializing medicines.
With passage of the Inflation Reduction Act (IRA) in the rearview mirror, policymakers are continuing their charge to address drug prices and the pharmaceutical supply chain, uprooting the status quo of market access in the US and beyond.
Join our webcast to gain new insights from Ernst & Young LLP (EY US) policy and strategy professionals about the market implications for life sciences companies around the evolving policy landscape.
Learn more about:
- Next steps and analysis following announcement of the first 10 drugs selected for the IRA’s drug negotiation program
- Leading transparency legislation and regulatory action to shine a light on the pharmaceutical supply chain and M&A
- Evolving policy in access and coverage, from upcoming Medicaid payment changes to Medicare coverage and payment for innovative drugs
- Life sciences industry implications and potential disruption for manufacturers, wholesalers, pharmacy benefit managers, payers, patients and beyond
Presenters:
- Arda Ural, PhD, Principal and EY Americas Industry Markets Leader, Health Sciences & Wellness, Ernst & Young LLP
- Muna Tuna, Principal and EY US Market Access, Pricing and Reimbursement Leader, Health Sciences & Wellness, Ernst & Young LLP
- Heather Meade, Principal, Washington Council Ernst & Young, Ernst & Young LLP
- Laura Dillon, Senior Manager, Washington Council Ernst & Young, Ernst & Young LLP
- Joshua P. Cohen, Analyst, Joshua P. Cohen Healthcare Analytics, LLC
Webcast
CPE credits: 1.0
Time
your local time
